Deintensifying diabetes medications: Beliefs and misconceptions among older adults
Pilla SJ, Meza KA, Schoenborn NL, Boyd CM, Maruthur NM, Chander G. A Qualitative Study of Perspectives of Older Adults on Deintensifying Diabetes Medications [published
USDeN-Funded Pilot & Grant Planning Award Application Information Session (2023-2024 Cycle)
October 21, 2022 | 2:00 – 3:00 PM Eastern / 11:00 – 12:00 PM Pacific Presenter(s): Drs. Amanda Mixon & Sandra Simmons DOWNLOAD PRESENTATION POWERPOINT (PDF) »
Gabapentin as a substitute for opioids: Is the solution creating new problems?
Bongiovanni T, Gan S, Finlayson E, et al. Prolonged use of newly prescribed gabapentin after surgery [published online ahead of print, 2022 Aug 24]. J
USDeN-Funded CIH Interventions to Support Deprescribing of Benzodiazepine Receptor Agonist Pilot Award Application Information Session
October 11, 2022 | 2:00 – 3:00 PM Eastern / 11:00 – 12:00 PM Pacific Presenter(s): Drs. Amanda Mixon & Sandra Simmons DOWNLOAD PRESENTATION POWERPOINT (PDF) »
Is there a Role for Pharmacoepidemiology in Deprescribing Research?
October 6, 2022 | 12:00 – 1:00 PM Eastern / 9:00 – 10:00 AM Pacific The session, hosted by the International Society for Pharmacoepidemiology (ISPE), will
The Tool to Reduce Inappropriate Medications (TRIM): Can a clinical decision support tool promote deprescribing among primary care clinicians?
Mecca MC, Zenoni M, Fried TR. Primary care clinicians’ use of deprescribing recommendations: A mixed-methods study. Patient Educ Couns. 2022;105(8):2715-2720. doi:10.1016/j.pec.2022.04.013 The Tool to Reduce
A Novel Deprescribing Quality Metric for Health Plans: The HEDIS Deprescribing of Benzodiazepines in Older Adults Measure
https://youtu.be/dYyeuJujaQw
Is there a Role for Pharmacoepidemilogy in Deprescribing Research?
October 6, 2022 | 12:00 – 1:00 PM Eastern / 9:00 – 10:00 AM Pacific
Deprescribing Interventions: Learnings from an Overview of Systematic Reviews
https://youtu.be/6g5nHveow1Y Rigorous evidence to guide deprescribing is limited, and priorities to inform deprescribing research and practice remain unclear. Further, it is not known if there
Can N-of-1 trials inform deprescribing practices? Dr. Parag Goyal weighs in
Goyal P, Safford M, Hilmer SN, et al. N-of-1 Trials to Facilitate Evidence-Based Deprescribing: Rationale and Case Study [published online ahead of print, 2022 Jun
